INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Radhakrishnan Maha reported TRDA

Director · Entrada Therapeutics, Inc. · Entrada Therapeutics, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
19.0K
Price
—
Executed
Jun 10, 2026
Disclosed
Jun 12, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 10 executedJun 12, 2026 disclosed

TRDA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TRDA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    24
    PK
    Parmar KushDirector
    TRDAEntrada Therapeutics, Inc.
    Open-market sale
    		SELL$73K
    10.5K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    23
    PK
    Parmar KushDirector
    TRDAEntrada Therapeutics, Inc.
    Open-market sale
    		SELL$647K
    92.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    23
    PK
    Parmar KushDirector
    TRDAEntrada Therapeutics, Inc.
    Open-market sale
    		SELL$358K
    52.3K sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    3
    DJ
    Dowden Nathan JPresident & COO
    TRDAEntrada Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$26K
    15.0K sh
    		May 4, 2026May 4, 2026
    traded May 4, 2026
    		+0dSEC FORM 4

    Evidence

    7
    DJ
    Dowden Nathan JPresident & COO
    TRDAEntrada Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    15.0K sh
    		May 4, 2026May 4, 2026
    traded May 4, 2026
    		+0dSEC FORM 4

    Evidence

    17
    DJ
    Dowden Nathan JPresident & COO
    TRDAEntrada Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$230K
    15.0K sh
    		May 4, 2026May 4, 2026
    traded May 4, 2026
    		+0dSEC FORM 4

    Evidence

    20
    SN
    Sethuraman NatarajanPresident, Research & Develop.
    TRDAEntrada Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$399K
    25.9K sh
    		May 4, 2026May 4, 2026
    traded May 4, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002013423-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 10, 2026
    Published
    Jun 12, 2026
    Ingested by INSIDER
    Nov 5, 03:53 UTC
    Last re-read
    Nov 5, 03:53 UTC

    Extracted facts

    Filer
    Radhakrishnan Maha
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Entrada Therapeutics, Inc. — Stock Option (Right to Buy)
    Ticker
    TRDA
    Shares
    19.0K
    Price per share
    $0
    Execution date (reported)
    Jun 10, 2026
    Owned after transaction
    19.0K shares
    Days from execution to publication
    2

    What this establishes

    Radhakrishnan Maha filed this Form 4 reporting a grant or award of TRDA on Jun 10, 2026. It became public on Jun 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Radhakrishnan Mahacik:0002013423
    Issuer
    Entrada Therapeutics, Inc.cik:0001689375

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.